|
Press Releases |
|
 |
|
Monday, August 2, 2021 |
|
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures |
Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older" in China from the National Medical Products Administration. more info >> |
|
Friday, July 30, 2021 |
|
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) |
Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) -- granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021. more info >> |
|
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021 |
Biogen and Eisai Co., Ltd. today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer's disease called ICARE AD-US, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
Thursday, July 29, 2021 |
|
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment |
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 20th consecutive year since its initial inclusion in 2002. more info >> |
|
Tuesday, July 27, 2021 |
|
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 |
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC. more info >> |
|
Friday, July 23, 2021 |
|
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma |
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma. more info >> |
|
Wednesday, July 21, 2021 |
|
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 |
Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
Monday, July 19, 2021 |
|
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand |
Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. more info >> |
|
Thursday, July 1, 2021 |
|
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong |
Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
Thursday, June 24, 2021 |
|
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) |
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 3, 2025 22:10 JST
|
|
|
AI Paradox in QA: Twice as Many Testers Fear Job Loss, But Adoption Keeps Climbing
Apr 3, 2025 20:06 HKT/SGT
|
|
|
The India Market Entry Dilemma: What's Holding Manufacturers Back
Apr 3, 2025 19:30 HKT/SGT
|
|
|
Connect Marketplace Hong Kong 2025 Concludes Successfully
Apr 3, 2025 18:29 HKT/SGT
|
|
|
JBM Healthcare Completes Acquisition of 90% Interest in Tin Hee Tong
Apr 3, 2025 17:30 HKT/SGT
|
|
|
Guinean Artist Elie Kamano to Release New Single Exploring Africa's Colonial Past
Apr 3, 2025 17:00 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Apr 3, 2025 17:00 HKT/SGT
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Apr 3, 2025 16:41 HKT/SGT
|
|
|
JF SmartInvest Holdings Ltd Announces 2024 Annual Results
Apr 3, 2025 15:59 HKT/SGT
|
|
|
AEON CREDIT SERVICE (ASIA) COMPANY LIMITED FY2024/25 Revenue Up to HK$1,759.3 million with Net Profit of HK$400.5 million
Apr 3, 2025 14:04 HKT/SGT
|
|
|
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 3, 2025 7:00 JST
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 2, 2025 22:03 HKT/SGT
|
|
|
Doubleview Gold Corp 2025 Exploration Program
Apr 2, 2025 21:00 HKT/SGT
|
|
|
Hola Prime Launches Industry-First One-on-One Mentorship from Market Experts
Apr 2, 2025 20:00 HKT/SGT
|
|
|
Innovation Beverage Group Expands U.S. Distribution of its Award-Winning Bitters Through One of the Nation's Largest Beverage Alcohol Distributors
Apr 2, 2025 19:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|